10
Participants
Start Date
October 31, 2024
Primary Completion Date
July 31, 2029
Study Completion Date
October 31, 2029
Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
Peking University People's Hospital, Beijing
Peking Union Medical College Hospital
OTHER
Peking University Third Hospital
OTHER
Huazhong University of Science and Technology
OTHER
Tianjin Medical University
OTHER
Shandong University
OTHER
Shengjing Hospital
OTHER
Beijing Chao Yang Hospital
OTHER
Peking University People's Hospital
OTHER